Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.

ABSTRACT: Breast cancer is the leading cause of cancer-related deaths among women globally. The difficulties with anticancer medications, such as ineffective targeting, larger doses, toxicity to healthy cells and side effects, have prompted attention to alternate approaches to address these difficulties. RNA interference by small interfering RNA (siRNA) is one such tactic. When compared with chemotherapy, siRNA has several advantages, including the ability to quickly modify and suppress the expression of the target gene and display superior efficacy and safety. However, there are known challenges and hurdles that limits their clinical translation. Decomposition by endonucleases, renal clearance, hydrophilicity, negative surface charge, short half-life and off-target effects of naked siRNA are obstac

SUBMITTER: Sai BM 

PROVIDER: S-EPMC11498026 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature